Fulcrum Therapeutics, Inc. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 48/100
What the filing says
Alan Musso (CFO) voluntarily retiring; extended through Sept 30, 2026 or new CFO appointment, then consulting through Feb 8, 2027 at $5,000/month. Receives $366,000 transition pay (9 months salary, reduced by consulting fees), $195,200 target bonus (100% of 2026), 9 months COBRA subsidy, and 12-month stock option exercise window. Separately, three executives (Musso, Sapir, Oltmans) amended agreements on June 5, 2026 to add 1.0x Target Bonus retention bonuses if they remain through a Change in Control or experience qualifying terminations; such bonuses triggered in six-month pre-Change in Control windows.
Why this rating
CFO departure is material governance event; ~$561k direct cash cost (~0.19% of $296M market cap). Retention bonuses on three execs signal M&A risk/readiness. Not transformational alone but indicates potential strategic shifts ahead.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.